Abstract:

Objective To observe the effects and safety of intercalated combination of recombinant human endostatin（endostar） and cisplatin by intraperitoneal injection in mice model bearing tumor ascite. Methods The tumor ascites model were established with hepatocellular carcinoma H22 cell lines by intraperitoneal injection. One hundred and twenty ICR mice were randomly assigned into 4 groups： control group（normal saline d1-d10）， endostar group（endostar 8mg／kg，d1-d5， d7-d10； normal saline d6）， cisplatin group（cisplatin 0.04mg／kg，d6； normal saline d1-d5, d7-d10） and combined group（endostar 8mg／kg， d1-d5, d7-d10；cisplatin 0.04mg／kg，d6）. Body weight， volume of ascites， the number of tumor cells and red cells were measured. The peritoneum permeability assay， blood routine， liver function and renal function were tested in each group respectively. Implantation metastasis of tumor was observed in abdominal cavity of mice. Apoptosis of tumor cells in the ascites fluid were detected by flow cytometry. Survival time of each mouse was recorded. Results Compared with the control group， endostar group， cisplatin group and combined group could inhibit ascites accumulation， reduce the counts of tumor cells and red cells in the ascites fluid and tumor burden of abdominal cavity， as well as prolonging survival of mice（P＜0.05）. In those above items， combined group showed statistic significance compared with endostar group and cisplatin group（P＜0.05）. Combined group significantly increased apoptosis of tumor cells compared with control group and endostar group（P＜0.05）， but showed no difference with cisplatin group（P＞0.05）. Combined group obviously inhibited the peritoneum permeability compared with control group and cisplatin group（P＜0.05）， but showed no difference with endostar group（P＞0.05）. Peritoneal metastasis and weight gain were less in combined group compared with the other 3 groups. Blood routine， liver function and renal function of the each group were normal. Conclusion The intercalated combination of endostar and cisplatin by intraperitoneal injection treating H22 mice bearing tumor ascite has ideal effect and safety.